Analysts pointed out that the current biomedical valuation is cost-effective, and short-term recommendations are to pay attention to segments and stocks
with high growth or expected to exceed expectations.
Among them, in the Chinese medicine section, it is recommended to pay attention to Chinese medicine formula granules and brand OTC
.
For example, due to the clinical shortage of traditional Chinese medicine formula granules to national standards and the impact of the epidemic, the revenue of Red Sun Pharmaceutical Co.
, Ltd.
has grown relatively well in Q3, with a slight year-on-year decline, and it is expected that Q4 is expected to turn positive year-on-year, and volume and price are expected to rise and grow rapidly in
2023.
Brand OTC China Resources Sanjiu Q3 quarterly performance exceeded 35%; Sunflower Pharmaceutical's performance growth rate in the first three quarters is expected to exceed 20%.
Red Sun Pharmaceutical is expected to grow rapidly in volume and price in 2023
Hongri Pharmaceutical is a traditional Chinese medicine enterprise controlled by Tianjin State-owned Assets Supervision and Administration Commission, which currently has a layout of traditional Chinese medicine formula granules, finished drugs, medical devices, raw and auxiliary materials, medical and health services and intelligent supply chain
of pharmaceutical devices.
For Red Sun Pharmaceutical, the business of Chinese medicine formula granules and pieces series is an important business, the pilot work of Chinese medicine formula granules has ended on November 1, 2021, and in the future, the implementation of the whole process of production management, authentic medicinal materials have become a trend, and it is clearly proposed to concoct Chinese medicine pieces for the production of Chinese medicine formula granules by themselves, and do not allow the purchase of drinking pieces, which is beneficial to enterprises in the upstream layout of the
supply chain.
Data show that in 2021, Red Sun Pharmaceutical will achieve operating income of 7.
671 billion yuan, a year-on-year increase of 18.
22%.
Among them, Chinese medicine formula granules and pieces accounted for a high proportion
of revenue.
The industry predicts that Red Sun Pharmaceutical's revenue Q3 may achieve good growth compared with the previous month, and it is expected to rise in volume and price in 2023
.
The industry said that thanks to the rapid growth of China's economy in recent years, the increase in national income, the improvement of people's health awareness, the people's consumption expenditure in health has shown a rapid growth trend, health has become the fashion of today's society, and the progress of science and technology is also helping
people's healthy life.
With continuous innovation drive, the three-dimensional ecological construction of products and services, Redsun Pharmaceutical has gradually taken the lead in the era of big health
.
China Resources 39 achieved a year-on-year increase in net profit of nearly 37% in the third quarter of this year
Recently, China Resources Sanjiu released the first three quarters of 2022 performance report, showing that from January to September 2022, the company's total operating income increased by 7.
53% year-on-year to 12.
111 billion yuan, the net profit attributable to shareholders of listed companies increased by 11.
17% year-on-year to 1.
952 billion yuan, and the net profit attributable to shareholders of listed companies after deducting non-recurring profits and losses increased by 10.
08% year-on-year to 1.
783 billion yuan
。 In the third quarter, China Resources Sanjiu achieved a year-on-year increase of 9.
18% in total operating income to 3.
710 billion yuan; a net profit attributable to shareholders of listed companies increased by 36.
52% year-on-year to 519 million yuan; and net profit attributable to shareholders of listed companies after deducting non-recurring profits and losses increased by 27.
17% year-on-year to 451 million yuan
.
China Resources Sanjiu said that the growth rate of revenue and net profit in the third quarter was basically in line with expectations, mainly driven by the CHC business, of which cold medicine recovered well in the third quarter, mainly due to the relaxation of the sales management of the four types of drugs for epidemic prevention and control; increased incidence of cold medicines; The base was low
in the third quarter of the same period last year.
In addition, pediatrics, stomach medicine, and skin medicine performed well
from 1 to 8 months.
The business structure may change in the first three quarters compared with the first half of the year, mainly because the CHC business performed more prominently
in the first three quarters.
According to the company's announcement, the future driving factors of CR Sanjiu CHC business mainly are: 1) Relying on brand building barriers to expand OTC business, the company has continued to increase brand investment in recent years, attracting more young people; 2) Constantly expand new channels
.
In the past few years, the company has continued to lay out new channels, through product structure adjustment and professional team to adapt to the future development trend of online business; 3) Enriching products
.
Through acquisitions and other means, we continue to enrich the product pipeline and continuously extend the category
.
The industry said that it is optimistic about the long-term development ability of
CR Sanjiu.
Sunflower Pharmaceutical's performance growth rate in the first three quarters is expected to exceed 20%
According to the data, Sunflower Pharmaceutical is a brand OTC enterprise
integrating drug research and development, manufacturing and marketing.
The company's products cover six major therapeutic fields of pediatrics, gynecology, digestive system, respiratory cold, rheumatic bone disease, cardiovascular and cerebrovascular, with more than 300 varieties on sale and more than 1,000 reserve varieties
.
The company focuses on small sunflower medicines, supplemented by gynecological drugs and geriatric chronic diseases, and has now formed three characteristic categories
of "one small, one woman, and one old".
At the same time, the company adopts the characteristic "brand, general medicine, prescription, big health" combined marketing model, implements the dual-brand driving strategy of "Little Sunflower" and "Sunflower", and is an OTC enterprise
with outstanding brand capabilities.
In terms of profitability, Sunflower Pharmaceutical's gross profit margin has maintained 58-60% in recent years, and its net profit margin has shown a steady upward trend, with the company's net profit margin reaching 17.
09% in 2021, about 7 percentage points
higher than in 2016.
Data show that in the first half of this year, Sunflower Pharmaceutical's operating income increased by 7.
01% year-on-year to 2.
249 billion yuan, of which the revenue of traditional Chinese medicine, chemical medicine and health care products all achieved positive growth
.
In the first half of the year, the company's net profit attributable to shareholders of listed companies increased by 30.
56% year-on-year to 401 million yuan
.
For the performance expectations for the second half of the year, the company revealed that due to the characteristics of the payment cycle of the pharmaceutical industry and the high incidence of respiratory system in the cold season, pharmaceutical companies usually have a higher revenue growth rate in the fourth quarter than in other seasons
.
In addition, the industry predicts that Sunflower Pharmaceutical's performance growth rate in the first three quarters of this year is expected to exceed 20%.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
